What question did this study set out to answer?

The aim was to identify genetic and nongenetic factors that influence clopidogrel response in Egyptian patients.

January 12, 2016Clinical and Translational ScienceOpen Access

Genetic and Nongenetic Factors Affecting Clopidogrel Response in the Egyptian Population

View Full Paper

Ask AI

Bookmark

Why the study?

Does the presence of CYP2C19 loss-of-function alleles increase the risk of MACE in Egyptian patients with ACS or PCI treated with clopidogrel?

Key Points

The aim was to identify genetic and nongenetic factors that influence clopidogrel response in Egyptian patients.
190 Egyptians with acute coronary syndrome or percutaneous coronary intervention were genotyped.
Genetic variants tested included CYP2C19 *2, *3, *6, *8, *10, *17, CES1 G143E, and ABCB1*6 and *8.
Logistic regression analysis assessed associations with major adverse cardiac events.
CYP2C19 loss-of-function allele carriers had a higher risk of major adverse cardiac events (odds ratio 2.52; 95% CI 1.23-5.15, P=0.011).
Age was significantly associated with major adverse cardiac events (P=0.032).
Body mass index was also a significant predictor for MACE incidence in clopidogrel-treated patients (P=0.039).

Structured PICO

Does the presence of CYP2C19 loss-of-function alleles increase the risk of MACE in Egyptian patients with ACS or PCI treated with clopidogrel?

Population

190 Egyptians with acute coronary syndrome (ACS) and/or percutaneous coronary intervention (PCI)

Intervention

Clopidogrel (75 mg/day) for at least a month in carriers of CYP2C19 loss-of-function (LOF) alleles

Comparator

Noncarriers of CYP2C19 loss-of-function (LOF) alleles

Outcome

Major adverse cardiac events (MACE)composite

CYP2C19 loss-of-function variants, along with age and BMI, are significant predictors of MACE in Egyptian patients receiving clopidogrel after ACS or PCI.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

May warrant CYP2C19 testing consideration in Egyptian clopidogrel-treated ACS/PCI patients; leaves open need for prospective outcome trials.

Cite This Study

Khalil et al. (2016) studied this question.

synapsesocial.com/papers/69d71948424c1fc5df5637b5 https://doi.org/10.1111/cts.12383

Topics

Women and heart disease

View Full Paper

Ask AI

Bookmark

Implication

May warrant CYP2C19 testing consideration in Egyptian clopidogrel-treated ACS/PCI patients; leaves open need for prospective outcome trials.

Genetic and Nongenetic Factors Affecting Clopidogrel Response in the Egyptian Population

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Topics

Genetic and Nongenetic Factors Affecting Clopidogrel Response in the Egyptian Population

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Also Consider

Topics

Also Consider